

Egyptian Herbal Monograph

Volume 4

Herbal Formulations used in Egypt

Egyptian Drug Authority (EDA)

2024



Egyptian Herbal Monograph

Herbal Formulations Used in Egypt

Camel grass weed/ Toothpick

حلفابر و خلة بلدي

1. Names & Synonyms

Camel grass weed

Cymbopogon proximus (Hochst. ex A. Rich.) (1, 2):

Family: Gramineae (Poaceae) (2, 3).

Synonyms (3):

Andropogon proximus (Hochst.), *Andropogon sennarensis* (Hochst.), *Andropogon jwarancusa* Jones var. *proximus* (Hochst. ex A. Rich.), *Andropogon jwarancusa* Jones var. *sennarensis* (Hochst.) and *Cymbopogon sennarensis* (Hochst.).

Arabic Names: Halfa bar حلفابر, Mahareb محاريب (1, 4).

English Names: Camel grass, Camel's hay, Geranium grass, Scenanth (1, 2).

Toothpick

Ammi visnaga L. (1, 2, 5):

Family: Umbelliferae (Apiaceae).

Synonyms: *Daucus visnaga* L.

Arabic Names: Khella baladi خلة بلدى, Khella خلة, Gazar sheitani جزر شيطاني, Kammon habashi كمون حبشي.

English Names: Pick-tooth, Toothpick, Bishop's weed.

2. Parts used for medicinal purpose

Camel grass weed: Aerial parts (1).

Toothpick: Fruits and leaves (1, 2, 5).

3. Major chemical constituents

Camel grass weed:

-Essential Oil (4, 6): Piperitone, β -elemol, α -eudesmol, β -eudesmol, β -elemene, eudesm-7(11)-en-4-ol, D-limonene, 2-, α -terpineol, τ -cadinol, terpinolene, β -selinenol, 3-cyclohexen-1-one, 2-isopropyl-5-methy, 4-carene, shyobunol, cadina-1(10),4-diene, (-)-guaia-6,9-diene and β -caryophyllaneare.

-Sesquiterpenoids: Proximadiol (biocyclic sesquiterpene diol) in addition to 5 α -hydroxy- β -eudesmol, 1 β -hydroxy- β -eudesmol, 1 β -hydroxy- α -eudesmol, 5 α -hydroperoxy- β -eudesmol and 7 α , 11-dihydroxycadin- 10(14)-ene (1, 7).

-Others: Saponins, tannins, triterpenes, flavonoids, alkaloids, phenolic glycosides, cardiac glycosides and steroids (8).

Toothpick:

-Furanochromone derivatives (γ -Pyrones): Khellin, visnagin, khellinol, ammiol, visammiol, khellol, khellinin, khellinone, visnaginone (9) and visamminol.

-Pyrancoumarins/visnagans: Samidin, dihydrosamidin and visnadin (9).

-Furanocoumarins: Xanthotoxin, ammoidin, bergapten, and psoralen (10-17).

-Flavonoids: Quercetin, kaempferol, rhamnocitrin, rhamnetin and rhamnazin. Flavonoidal glycosides include quercetin-3-O-glucoside, kaempferol-3-O-glucoside and isorhamnetin 3-O-glucoside, rhamnetin-3-O-glucoside, isorhamnetin-3-O-glucoside, rhamnazin-3-O-glucoside, isorhamnetin-7-O-glucoside, quercetin-7, 3, 3'-O-triglucoside, quercetin-3-O-rutinoside, kaempferol-3-rutinoside and isorhamnetin-3-O-rutinoside.

-Flavonoidal sulfates: Quercetin 3-sulfate, rhamnocitrin 3-sulfate, and isorhamnetin-3-sulfate (18).

-Essential Oil: Oxygenated monoterpenes (linalool and thymol), monoterpene hydrocarbons (α -thujene, α -pinene, β -pinene, and β -myrcene) (18), and nonterpene derivatives (isoamyl 2-methylbutyrate, isoamyl isobutyrate, isobutyl 2-methylbutyrate, 2-methylbutyl 2-methylbutyrate, 2-methylbutyl isobutyrate, and isoamyl isovalerate) (19, 20).

-Sterols and Fatty acids: β -Sitosterol and β -sitosterol-glucoside (21), in addition to palmitic, palmitoleic, stearic, petroselinic, linoleic, linolinic, arachidic and tetracosanoic acids (18).

4. Medicinal uses (Indications)

Urinary tract disorders (22, 23, 24):

A. Diuretic (6, 7), renal colic pain killer (25, 26).

B. Break up and removal of small renal stones from urinary tract (Lithotriptic agent) (25).

5. Herbal preparations correlated to medicinal use

Combination of *C. proximus* herb (Extraction solvent 70% ethanol) dry extract and *A. visnaga* fruits (Extraction solvent 30% ethanol) dry extract.

Herbal preparation is in pharmaceutical dosage forms for oral use. The pharmaceutical form should be described by the pharmacopoeia full standard term.

6. Posology and method of administration correlated to medicinal use

Single dose: Combination of 72mg *C. proximus* dry extract and 180mg *A. visnaga* dry extract.

Daily dose: 3 times daily.

Method of administration: Oral use.

7. Contraindications

Hypersensitivity to the active substances and to other plants of the same family.

8. Special warnings and precautions for use

-If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist should be consulted.

-The exposure to sun or other sources of ultraviolet light should be avoided during treatment, in order to minimize photosensitivity due to *A. visnaga* content (27).

-Patients should be monitored for ophthalmologic changes, as *A. visnaga* has been associated with the development of severe ophthalmologic changes, particularly pigmentary retinopathy (28, 30).

-Blood glucose level should be monitored regularly.

-To be used under medical supervision.

9. Interactions with other medicinal products and other forms of interaction

Concurrent use with blood thinners, calcium channel blockers or blood pressure lowering drugs is avoided due to *A. visnaga* content (23).

10. Fertility, pregnancy and lactation

- The use during pregnancy should be avoided (24).

- Safety during lactation has not been established. In the absence of sufficient data, the use during lactation is not recommended.

- No fertility data available.

11. Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been performed.



12. Undesirable effects

- If adverse reactions occur, a doctor or a pharmacist should be consulted.
- Pseudoallergic reactions and reversible cholestatic jaundice and elevated activities of liver transaminases and γ -glutamyltransferase have been observed. These symptoms are typically reversible when the use is discontinued (27).

13. Overdose

Long term use or overdose of the drug can lead to queasiness, dizziness, loss of appetite, headache, sleep disorders and with very high dosage (corresponding to over 100 mg khellin), it caused reversible elevation in the levels of liver enzymes (27, 29).

14. Relevant biological properties

Not required as per Egyptian guidelines for registration of herbal medicines.

15. Additional information

-

16. Date of compilation/last revision

20/8/2023.

References

1	Batanouny, K. H. (1999). Wild Medicinal Plants in Egypt. (With contribution: E. Aboutabl, M. Shabana & F. Soliman). Academy of Scientific Research and Technology, Egypt. The World Conservation Union (IUCN).
2	Boulos, L. (2000). Flora of Egypt, Al Hadara Publishing, Cairo, Egypt.
3	Ibrahim A. Saleh and Mohamed Elamir F. Hegazy (2018). <i>Cymbopogon proximus</i> . In: Egyptian Encyclopedia of Wild Medicinal Plants, 6, 390-399. Academy of Scientific Research and Technology, Cairo, Egypt.
4	Malin, M. A., Ali, M. M. and Ramadhani, A. M. (2018). GC-MS analysis and antimicrobial activities of <i>Cymbopogon proximus</i> essential oil and phytochemical screening of its crude extracts. <i>Journal of Medicinal Plants Studies</i> , 6(4), 117-122.
5	Nahed, M. H. and Mona, M. A. (2017). <i>Ammi visnaga</i> L. In: Egyptian Encyclopedia of Wild Medicinal Plants, 2, 121-136. Academy of Scientific Research and Technology, Cairo, Egypt.
6	El-Tahir K. E. H. and Abdel Kader M. S. (2008). Chemical and pharmacological study of <i>Cymbopogon proximus</i> volatile oil. <i>Research journal of medicinal plant</i> , 2, 53-60.
7	El-Askary, H. I., Meselhy, M. R., Galal, A. M., (2003). Sesquiterpenes from <i>Cymbopogon proximus</i> . <i>Molecules</i> , 8, 670-677.
8	Ali, M. R. (2012). Antibacterial and phytochemical screening <i>Lepidium sativum</i> and <i>Cymbopogon schoenanthus</i> . BSc thesis, Faculty of Science, Khartoum University.
9	Hashim, S., Jan, A., Marwat, K. B. and Khan, M. A. (2014). Phytochemistry and medicinal properties of <i>Ammi visnaga</i> (Apiaceae). <i>Pak. J. Bot.</i> , 46(3): 861-867.
10	Abou-Mustafa, E. A., Saleh, N. A. M., Elgamal, M. H. A., Shalaby, N. M. M. and Duddeck, H. (1990). A further contribution to the γ -pyrone constituents of <i>Ammi visnaga</i> fruits. <i>Planta Medica</i> , 56, 134.
11	Martelli, P., Bovalini, L., Ferri, S. and Franchi, G. G. (1984). Rapid separation and quantitative determination of Khellin and Visnagin in <i>Ammi visnaga</i> (L.) Lam Fruits by High Performance Liquid-Chromatography. <i>J. Chromato.</i> , 301:297-302.
12	Eldomiaty, M. M. (1992). Improved high-performance liquid-chromatographic determination of khellin and visnagin in <i>Ammi visnaga</i> fruits and Pharmaceutical formulations. <i>J. Pharm. Sci.</i> , 81: 475-478.
13	Zgorka, G., Dragan, T., Głowniak, K. and Basiura, E. (1998). Determination of furanochromones and pyranocoumarins in drugs and <i>Ammi visnaga</i> fruits by combined solid-phase extraction, high-performance liquid chromatography and thin layer chromatography. <i>J. Chromato. A</i> , 797(1-2):305-309.
14	Balbua, S. I., Hilal, S. H. and Zaki, A. Y. (1976). Medicinal Plant Constituents. Second Edition, Central Agency for University and School Books, Cairo, Egypt.

15	El-Gamal, M. H., Shalaby, N. M., El-Hagrassy, A. M., Toth, G., Simon, A. and Duddeck, H. (1998). A further contribution to some gamma-pyrone constituents of <i>Ammi visnaga</i> . <i>Fitoterapia</i> , 69(6):549-550.
16	Sonnenberg, H., Kaloga, M., Eisenbach, N. and Frömming, K. K. (1995). Isolation and characterization of an angular-type dihydro-pyrano-coumarin-glycoside from the fruits of <i>Ammi visnaga</i> (L.) LAM. (Apiaceae). <i>J. Naturforsch</i> , 50(9-10): 729-731.
17	Razzaghi-Abyaneh, M., Shams-Ghahfarokhi, M., Rezaee, M.B. and Sakuda, S. (2010). Natural Aflatoxin Inhibitors from Medicinal Plants. In <i>Mycotoxins in Food, Feed and Bioweapons</i> ; Rai, M., Varma, A., eds.; Springer: Berlin/Heidelberg, Germany, 329-352.
18	Khalil, N., Bishr, M., Desouky, S. and Salama, O. (2020). <i>Ammi visnaga</i> L., a Potential Medicinal Plant: A Review. <i>Molecules</i> , 25: 301.
19	Zrira, S., Elamrani, A., Pellerin, P., Bessiere, J. M., Menut, C. and Benjilali, B. (2008). Isolation of Moroccan <i>Ammi visnaga</i> oil: comparison between hydrodistillation, steam distillation and supercritical fluid extraction. <i>J. Essent. Oil Bear. Plants</i> , 11: 30-35.
20	Abdul-Jalil, T.Z., Saour, K. and Nasser, A. A. (2010). Phytochemical study of some flavonoids present in the fruits of two <i>Ammi</i> L. species wildy grown in Iraq. <i>Iraqi J. Pharma. Sci.</i> , 19: 48-57.
21	Keddad, A., Baaliouamer, A. and Hazzit, M. (2016). Chemical composition and antioxidant activity of essential oils from umbels of Algerian <i>Ammi visnaga</i> (L.). <i>J. Essent. Oil Bear. Plants</i> , 19: 1243-1250.
22	Egyptian Pharmacopoeia (1984). General Organization for Government Printing, Cairo, 3 th ed.
23	Alam, S., Anjum, N., Akhtar, J. and Bashir, F. (2018). Pharmacological investigations on khella- (<i>Ammi visnaga</i> L.). <i>World Journal of Pharmaceutical Research</i> , 7(13):212-224.
24	WHO monographs on selected medicinal plants (2007). <i>Fructus Ammi Visnagae</i> , Volume 3, 23-32.
25	Selim, S. A. (2011). Chemical composition, antioxidant and antimicrobial activity of the essential oil and methanol extract of the Egyptian lemongrass <i>Cymbopogon proximus</i> Stapf. <i>Grasasy Aceites</i> , 62(1), 55-61.
26	Conservation and sustainable use of medicinal plants in Egypt, National Surveys. (2016). UNDP, GEF, ASRT and NRC, vol (1-5).
27	Blumenthal, M., Busse, W. R., Goldberg, A., Gruenwald, J., Hall, T., Riggins, C.W. and Rister, R. S. (eds.) Klein, S. and Rister, R.S. (1998). The complete German Commission E monographs, Austin, TX, American Botanical Council.
28	Shlosberg, A., Egyed, M. N. and Eilat, A. (1974). The comparative photosensitizing properties of <i>Ammi majus</i> and <i>Ammi visnaga</i> in goslings. <i>Avian Dis.</i> , 18(4):544-550.
29	PDR for Herbal Medicines (1998). Medical Economic Co. Montvale, New Jersey, 639. ISBN 1563633612, 9781563633614.
30	Vanachayangkul, P., Chow, N., Khan, S.R. and Butterweck, V. (2011). Prevention of renal crystal deposition by an extract of <i>Ammi visnaga</i> L. and its constituents khellin and visnagin in hyperoxaluric rats. <i>Urol. Res.</i> , 39(3): 189-195.